Janusz Springer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Janusz Springer has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Tomasz Szmuda
Department of Neurosurgery, Medical University of Gdansk, Gdansk, Poland
11 shared publications - Przemyslaw Maciej Waszak
Department of Hygiene and Epidemiology, Medical University of Gdansk, 80-210 Gdansk, Poland
6 shared publications - Maciej Niedźwiecki
Department of Paediatrics, Haematology and Oncology, Medical University of Gdańsk, Skłodowskiej-Curie 3a, 80-210 Gdansk, Poland
5 shared publications - Mieszko Czapliński
University Clinical Centre, Medical University of Gdańsk, Dębinki 7, 80-952 Gdańsk, Poland
5 shared publications Pawel Sloniewski
Neurosurgery Department, Medical University of Gdansk, Gdansk, Poland
4 shared publications- Wiesław Jerzy Cubała
Medical University of Gdansk
4 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8758
Clinical Presentations of Pseudomonas aeruginosa Infection in Children with Leukaemia Treated with Chemotherapy—A Series of 5 Cases with Discussion
Background: Ecthyma gangrenosum (EG) associated with Pseudomonas aeruginosa can be life-threatening in immunocompromised patients with haematological malignancies. Severe neutropenia and antimicrobial resistance complicate treatment, while the roles of surgery and supportive therapies remain uncertain. Methods: We retrospectively reviewed five paediatric patients with leukaemia who developed life-threatening P. aeruginosa infections during chemotherapy. Cases were identified through a tertiary paediatric oncology centre’s clinical registry and verified using archived medical records. Clinical, microbiological, therapeutic, and outcome data, including surgical interventions, supportive therapies, and chemotherapy interruptions, were analysed. Results: All five patients developed severe infections during chemotherapy. EG affected the perineal or genital region in several cases, including two cases of Fournier’s gangrene. Four patients underwent surgical excision or debridement; surgery was not feasible in one because of critical deterioration. All received antimicrobials, with regimens adjusted according to microbiological findings and susceptibility profiles. Supportive treatments included granulocyte colony-stimulating factor, immunoglobulins, and granulocyte transfusions. Two patients survived into adulthood, including one who remained in remission after haematopoietic stem cell transplantation; three died, one from infection-associated multiorgan failure before surgery, one following leukaemia relapse, and one from post-transplant complications. Infection and its treatment substantially delayed or modified chemotherapy. Conclusions: EG associated with P. aeruginosa during paediatric leukaemia treatment can cause death and disrupt anticancer therapy. Early multidisciplinary assessment, appropriate antimicrobial treatment, and timely surgical management of necrotic tissue should be considered when feasible. Immunomodulatory interventions and discharge between chemotherapy cycles may benefit selected patients, but their efficacy cannot be established from this small retrospective series. Further multicentre studies are needed to clarify optimal management.
- 9 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8758
Open AccessClinical Presentations of Pseudomonas aeruginosa Infection in Children with Leukaemia Treated with Chemotherapy—A Series of 5 Cases with Discussion
Background: Ecthyma gangrenosum (EG) associated with Pseudomonas aeruginosa can be life-threatening in immunocompromised patients with haematological malignancies. Severe neutropenia and antimicrobial resistance complicate treatment, while the roles of surgery and supportive therapies remain uncertain. Methods: We retrospectively reviewed five paediatric patients with leukaemia who developed life-threatening P. aeruginosa infections during chemotherapy. Cases were identified through a tertiary paediatric oncology centre’s clinical registry and verified using archived medical records. Clinical, microbiological, therapeutic, and outcome data, including surgical interventions, supportive therapies, and chemotherapy interruptions, were analysed. Results: All five patients developed severe infections during chemotherapy. EG affected the perineal or genital region in several cases, including two cases of Fournier’s gangrene. Four patients underwent surgical excision or debridement; surgery was not feasible in one because of critical deterioration. All received antimicrobials, with regimens adjusted according to microbiological findings and susceptibility profiles. Supportive treatments included granulocyte colony-stimulating factor, immunoglobulins, and granulocyte transfusions. Two patients survived into adulthood, including one who remained in remission after haematopoietic stem cell transplantation; three died, one from infection-associated multiorgan failure before surgery, one following leukaemia relapse, and one from post-transplant complications. Infection and its treatment substantially delayed or modified chemotherapy. Conclusions: EG associated with P. aeruginosa during paediatric leukaemia treatment can cause death and disrupt anticancer therapy. Early multidisciplinary assessment, appropriate antimicrobial treatment, and timely surgical management of necrotic tissue should be considered when feasible. Immunomodulatory interventions and discharge between chemotherapy cycles may benefit selected patients, but their efficacy cannot be established from this small retrospective series. Further multicentre studies are needed to clarify optimal management.
- Open Access
- 17 September 2026
- Published by MDPI AG in Pediatric Reports
- Vol. 18 (5) , 121
Long-Term Sequelae in Patients Treated for Recurrent CNS Relapses of Pediatric B-Cell Acute Lymphoblastic Leukemia: 20-Year Follow-Up, Neurological Consequences, and Survivorship Burden—A Case Report and Literature Review
Central nervous system (CNS) relapse remains a major cause of treatment failure in pediatric acute lymphoblastic leukemia (ALL). Repeated isolated CNS relapse is particularly rare and associated with poor prognosis, while optimal therapeutic strategies remain insufficiently defined. Intensified CNS-directed therapy may improve disease control but is also associated with substantial long-term neurotoxicity and survivorship burden. We present the case of a boy with favorable-risk B-cell ALL who developed two isolated CNS relapses despite a good initial response to frontline therapy and absence of classical CNS relapse risk factors. The second relapse was associated with extensive meningeal involvement and optic nerve infiltration. The patient underwent intensive multimodal CNS-directed therapy, including repeated intrathecal chemotherapy, liposomal cytarabine administered according to the IntReALL 2010 protocol, cranial irradiation, and allogeneic hematopoietic stem cell transplantation (alloHSCT) from a matched sibling donor. Durable long-term remission was achieved despite the extremely unfavorable prognosis that is associated with a second isolated CNS relapse. A twenty-year follow-up extending into early adulthood revealed substantial late complications, including epilepsy, transient ischemic attack, optic nerve injury, endocrinopathies, obesity, secondary thyroid malignancy, neurocognitive difficulties, and depression requiring long-term psychiatric and psychological support. The present case illustrates the complex balance between effective CNS disease control and cumulative treatment-related neurotoxicity in pediatric ALL survivors. It also highlights the cumulative CNS injury and long-term survivorship burden that is associated with repeated CNS relapse and multimodal CNS-directed therapy.
- 17 September 2026
- Published by MDPI AG in Pediatric Reports
- Vol. 18 (5) , 121
Open AccessLong-Term Sequelae in Patients Treated for Recurrent CNS Relapses of Pediatric B-Cell Acute Lymphoblastic Leukemia: 20-Year Follow-Up, Neurological Consequences, and Survivorship Burden—A Case Report and Literature Review
Central nervous system (CNS) relapse remains a major cause of treatment failure in pediatric acute lymphoblastic leukemia (ALL). Repeated isolated CNS relapse is particularly rare and associated with poor prognosis, while optimal therapeutic strategies remain insufficiently defined. Intensified CNS-directed therapy may improve disease control but is also associated with substantial long-term neurotoxicity and survivorship burden. We present the case of a boy with favorable-risk B-cell ALL who developed two isolated CNS relapses despite a good initial response to frontline therapy and absence of classical CNS relapse risk factors. The second relapse was associated with extensive meningeal involvement and optic nerve infiltration. The patient underwent intensive multimodal CNS-directed therapy, including repeated intrathecal chemotherapy, liposomal cytarabine administered according to the IntReALL 2010 protocol, cranial irradiation, and allogeneic hematopoietic stem cell transplantation (alloHSCT) from a matched sibling donor. Durable long-term remission was achieved despite the extremely unfavorable prognosis that is associated with a second isolated CNS relapse. A twenty-year follow-up extending into early adulthood revealed substantial late complications, including epilepsy, transient ischemic attack, optic nerve injury, endocrinopathies, obesity, secondary thyroid malignancy, neurocognitive difficulties, and depression requiring long-term psychiatric and psychological support. The present case illustrates the complex balance between effective CNS disease control and cumulative treatment-related neurotoxicity in pediatric ALL survivors. It also highlights the cumulative CNS injury and long-term survivorship burden that is associated with repeated CNS relapse and multimodal CNS-directed therapy.
- Open Access
- 27 August 2026
- Published by MDPI AG in Preprints.org
Ecthyma Gangrenosum as Clinical Presentation of Pseudomonas aeruginosa Infection in Children with Leukaemia - A Case Series
Ecthyma gangrenosum (EG) is one of the manifestations of skin infections affecting immunocompromised patients. Pseudomonas aeruginosa is an important etiologic factor. The cutaneous localization of EG lesions usually is the consequence of bacteraemia. Neutropenia is the main risk factor for EG in patients with haematological malignancies. In this paper we present four cases of EG in children with acute leukaemia, who underwent chemotherapy and were treated with broad spectrum antibiotics, immunoglobulins and G-CSF. Granulocyte mass was given in three cases and one patient underwent hyperbaric treatment. All of those methods were insufficient and the patients did not improve until wide surgical excision of necrotic changes was done. The outcomes of severe EG were poor. Only in one case the patient recovered from infection and the leukaemia. One patient died of P. aeruginosa sepsis and septic shock. Two were healed of infection, but later died of leukaemia relapses. We conclude that EG leads to prolonged delays in haematological treatment and EG management should also include early surgical intervention to remove the necrotic lesions and to incise the regions of inflammatory changes.
- 27 August 2026
- Published by MDPI AG in Preprints.org
Open AccessEcthyma Gangrenosum as Clinical Presentation of Pseudomonas aeruginosa Infection in Children with Leukaemia - A Case Series
Ecthyma gangrenosum (EG) is one of the manifestations of skin infections affecting immunocompromised patients. Pseudomonas aeruginosa is an important etiologic factor. The cutaneous localization of EG lesions usually is the consequence of bacteraemia. Neutropenia is the main risk factor for EG in patients with haematological malignancies. In this paper we present four cases of EG in children with acute leukaemia, who underwent chemotherapy and were treated with broad spectrum antibiotics, immunoglobulins and G-CSF. Granulocyte mass was given in three cases and one patient underwent hyperbaric treatment. All of those methods were insufficient and the patients did not improve until wide surgical excision of necrotic changes was done. The outcomes of severe EG were poor. Only in one case the patient recovered from infection and the leukaemia. One patient died of P. aeruginosa sepsis and septic shock. Two were healed of infection, but later died of leukaemia relapses. We conclude that EG leads to prolonged delays in haematological treatment and EG management should also include early surgical intervention to remove the necrotic lesions and to incise the regions of inflammatory changes.
- Open Access
- 14 August 2026
- Published by MDPI AG in Preprints.org
Successful Treatment of Catastrophic Antiphospholipid Syndrome with Mycophenolate Mofetil in a Teenager Without Underlying Disease
Catastrophic antiphospholipid syndrome (CAPS) is a severe form of the antiphospholipid syndrome, a rare autoimmune disease characterized by the presence of antiphospholipid antibodies (APAs) directed against endothelial and plasma proteins in association with recurrent venous and/or arterial thromboembolic events and/or foetal loss. CAPS is marked by small vessel thrombosis, multiorgan failure and a mortality rate of up to 50%. The currently preferred treatment regimen for CAPS includes: anticoagulants, glucocorticosteroids, plasmapheresis with or without intravenous immunoglobulins. Our case of a paediatric CAPS patient is unusual for two reasons: 1) the patient did not suffer from SLE or any other risk factor correlated with increased possibility of thrombosis or CAPS and 2) it is probably the first published case demonstrating successful a remission of CAPS with the immunosuppressant mycophenolate mofetil (MMF) and anti-coagulants. Thus, our case highlights the need for further clinical trials of the effectiveness of new immunosuppressants in the treatment of CAPS and APS.
- 14 August 2026
- Published by MDPI AG in Preprints.org
Open AccessSuccessful Treatment of Catastrophic Antiphospholipid Syndrome with Mycophenolate Mofetil in a Teenager Without Underlying Disease
Catastrophic antiphospholipid syndrome (CAPS) is a severe form of the antiphospholipid syndrome, a rare autoimmune disease characterized by the presence of antiphospholipid antibodies (APAs) directed against endothelial and plasma proteins in association with recurrent venous and/or arterial thromboembolic events and/or foetal loss. CAPS is marked by small vessel thrombosis, multiorgan failure and a mortality rate of up to 50%. The currently preferred treatment regimen for CAPS includes: anticoagulants, glucocorticosteroids, plasmapheresis with or without intravenous immunoglobulins. Our case of a paediatric CAPS patient is unusual for two reasons: 1) the patient did not suffer from SLE or any other risk factor correlated with increased possibility of thrombosis or CAPS and 2) it is probably the first published case demonstrating successful a remission of CAPS with the immunosuppressant mycophenolate mofetil (MMF) and anti-coagulants. Thus, our case highlights the need for further clinical trials of the effectiveness of new immunosuppressants in the treatment of CAPS and APS.
- Open Access
- 7 August 2026
- Published by MDPI AG in Preprints.org
Intrathecal Liposomal Cytarabine as Bridge Therapy to Allogenic Hematopoietic Stem Cell Transplantation in Second Isolated CNS Relapse of Paediatric B-Cell Acute Lymphoblastic Leukaemia: 15-Year Follow-Up, Neurological Sequelae, and Survivorship Burden - A Case Report and Literature Review
Central nervous system (CNS) relapse remains a major cause of treatment failure in paediatric acute lymphoblastic leukaemia (ALL). Repeated isolated CNS relapse is particularly rare and associated with poor prognosis, while optimal therapeutic strategies remain insufficiently defined. Intensified CNS-directed therapy may improve disease control but is also associated with substantial long-term neurotoxicity and survivorship burden. We present the case of a boy with favourable-risk B-cell ALL who developed two isolated CNS relapses despite good initial response to frontline therapy and absence of classical CNS relapse risk factors. The second relapse was associated with extensive meningeal involvement and optic nerve infiltration. The patient underwent intensive multimodal CNS-directed therapy including repeated intrathecal chemotherapy, liposomal cytarabine administered according to the IntReALL 2010 protocol, cranial irradiation, and allogeneic hematopoietic stem cell transplantation (alloHSCT) from a matched sibling donor. Durable long-term remission was achieved despite the extremely unfavourable prognosis associated with second isolated CNS relapse. Fifteen-year follow-up extending into early adulthood revealed substantial late complications, including epilepsy, transient ischemic attack, optic nerve injury, endocrinopathies, obesity, secondary thyroid malignancy, neurocognitive difficulties, and depression requiring long-term psychiatric and psychological support. The present case illustrates the complex balance between effective CNS disease control and cumulative treatment-related neurotoxicity in paediatric ALL survivors. It also highlights the cumulative CNS injury and long-term survivorship burden associated with repeated CNS relapse and multimodal CNS-directed therapy.
- 7 August 2026
- Published by MDPI AG in Preprints.org
Open AccessIntrathecal Liposomal Cytarabine as Bridge Therapy to Allogenic Hematopoietic Stem Cell Transplantation in Second Isolated CNS Relapse of Paediatric B-Cell Acute Lymphoblastic Leukaemia: 15-Year Follow-Up, Neurological Sequelae, and Survivorship Burden - A Case Report and Literature Review
Central nervous system (CNS) relapse remains a major cause of treatment failure in paediatric acute lymphoblastic leukaemia (ALL). Repeated isolated CNS relapse is particularly rare and associated with poor prognosis, while optimal therapeutic strategies remain insufficiently defined. Intensified CNS-directed therapy may improve disease control but is also associated with substantial long-term neurotoxicity and survivorship burden. We present the case of a boy with favourable-risk B-cell ALL who developed two isolated CNS relapses despite good initial response to frontline therapy and absence of classical CNS relapse risk factors. The second relapse was associated with extensive meningeal involvement and optic nerve infiltration. The patient underwent intensive multimodal CNS-directed therapy including repeated intrathecal chemotherapy, liposomal cytarabine administered according to the IntReALL 2010 protocol, cranial irradiation, and allogeneic hematopoietic stem cell transplantation (alloHSCT) from a matched sibling donor. Durable long-term remission was achieved despite the extremely unfavourable prognosis associated with second isolated CNS relapse. Fifteen-year follow-up extending into early adulthood revealed substantial late complications, including epilepsy, transient ischemic attack, optic nerve injury, endocrinopathies, obesity, secondary thyroid malignancy, neurocognitive difficulties, and depression requiring long-term psychiatric and psychological support. The present case illustrates the complex balance between effective CNS disease control and cumulative treatment-related neurotoxicity in paediatric ALL survivors. It also highlights the cumulative CNS injury and long-term survivorship burden associated with repeated CNS relapse and multimodal CNS-directed therapy.
- Open Access
- 4 May 2026
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 27, e951547
Severe Anemia as a Rare Complication of Traumatic Scalp Arteriovenous Fistula: A Case Report
Severe Anemia as a Rare Complication of Traumatic Scalp Arteriovenous Fistula: A Case Report - Article abstract #951547
- 4 May 2026
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 27, e951547
Open AccessSevere Anemia as a Rare Complication of Traumatic Scalp Arteriovenous Fistula: A Case Report
Severe Anemia as a Rare Complication of Traumatic Scalp Arteriovenous Fistula: A Case Report - Article abstract #951547
- Open Access
- 31 January 2025
- Published by Medical Communications Sp. z.o.o. in Psychiatria i Psychologia Kliniczna
- Vol. 24 (3) , 240-244
Polish-language adaptation of the Oxford Depression Questionnaire (ODQ)
Emotional disorders associated with antidepressant treatment (e.g. anhedonia and emotional blunting) are significant clinical and research concerns which influence treatment effectiveness and patients’ quality of life. Nearly one-third of patients treated with antidepressants report experiencing apathy, with approximately 8% describing it as moderate to severe. Similarly, about 40% report a loss of motivation, with 12% characterising this symptom as moderate or severe. The Oxford Depression Questionnaire (ODQ) is a standardised tool developed to assess the severity, differentiation, and duration of emotional disorders related to the use of selective serotonin reuptake inhibitors (SSRI) antidepressants, distinguishing them from core depressive symptoms, such as anhedonia. The ODQ consists of 26 items divided into three sections, assessing weekly emotional experiences, changes compared to before the illness, and the influence of antidepressants on emotional functioning. This study presents the Polish-language adaptation of the ODQ, deemed appropriate for both clinical and research purposes, providing a robust tool for assessing SSRI-induced emotional changes and aiding in differential diagnosis and treatment planning.
- 31 January 2025
- Published by Medical Communications Sp. z.o.o. in Psychiatria i Psychologia Kliniczna
- Vol. 24 (3) , 240-244
Open AccessPolish-language adaptation of the Oxford Depression Questionnaire (ODQ)
Emotional disorders associated with antidepressant treatment (e.g. anhedonia and emotional blunting) are significant clinical and research concerns which influence treatment effectiveness and patients’ quality of life. Nearly one-third of patients treated with antidepressants report experiencing apathy, with approximately 8% describing it as moderate to severe. Similarly, about 40% report a loss of motivation, with 12% characterising this symptom as moderate or severe. The Oxford Depression Questionnaire (ODQ) is a standardised tool developed to assess the severity, differentiation, and duration of emotional disorders related to the use of selective serotonin reuptake inhibitors (SSRI) antidepressants, distinguishing them from core depressive symptoms, such as anhedonia. The ODQ consists of 26 items divided into three sections, assessing weekly emotional experiences, changes compared to before the illness, and the influence of antidepressants on emotional functioning. This study presents the Polish-language adaptation of the ODQ, deemed appropriate for both clinical and research purposes, providing a robust tool for assessing SSRI-induced emotional changes and aiding in differential diagnosis and treatment planning.
- 3 July 2024
- Published by Taylor & Francis in Advances in Mental Health
- Vol. 23 (2) , 158-174
The #BlueWhaleChallenge and presence of suicidal ideations on Polish-language Twitter
- 3 July 2024
- Published by Taylor & Francis in Advances in Mental Health
- Vol. 23 (2) , 158-174
The #BlueWhaleChallenge and presence of suicidal ideations on Polish-language Twitter
- Open Access
- 21 May 2024
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 31 (3) , 499-501
Effectiveness of antazoline versus amiodarone, flecainide, and propafenone in restoring sinus rhythm at the Emergency Department — case-match study
Atrial fibrillation (AF) is the most common arrhythmia among adults worldwide [1]. It is estimated that 19.2% of people ≥ 65 years of age in Poland have AF, most frequently paroxysmal [2].
- 21 May 2024
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 31 (3) , 499-501
Open AccessEffectiveness of antazoline versus amiodarone, flecainide, and propafenone in restoring sinus rhythm at the Emergency Department — case-match study
Atrial fibrillation (AF) is the most common arrhythmia among adults worldwide [1]. It is estimated that 19.2% of people ≥ 65 years of age in Poland have AF, most frequently paroxysmal [2].